Regulatory Storm Clouds Overshadow Hims & Hers' Record Financial Performance

Despite record 2025 revenue, telehealth stock crashes over 50% due to FDA action, patent lawsuit, SEC probe, and weak guidance, prompting a major acquisition for diversification.

Despite closing the 2025 fiscal year with record revenue and solid profitability, shares of telehealth provider Hims & Hers have faced a severe sell-off. Investor sentiment has been dominated not by the strong operational results, but by a confluence of regulatory challenges and legal threats that have driven the stock price down by more than half since the start of the year.

A Triple Blow from Regulators and the Courts

The dramatic decline is largely attributed to escalating issues within the company's GLP-1 weight-loss medication business. In a concentrated two-week period, the company was hit by three significant setbacks. First, the U.S. Food and Drug Administration (FDA) declared a lower-cost pill version of semaglutid offered by Hims & Hers to be an illegal copy, forcing its removal from the market.

Almost simultaneously, pharmaceutical giant Novo Nordisk filed a patent infringement lawsuit. Compounding these problems, the U.S. Securities and Exchange Commission (SEC) initiated an inquiry into the company's disclosure practices concerning its weight-loss segment. For shareholders, these mounting uncertainties have overwhelmingly outweighed the positive fundamentals.

Strong Earnings Met with Tepid Guidance

The company's robust financial achievements were nearly erased by these emerging risks. Hims & Hers reported a 59% increase in annual revenue for 2025, reaching approximately $2.35 billion, with net income of $128 million. However, the outlook for the coming quarter fell well short of market expectations.

Management's revenue forecast for Q1 now sits between $600 million and $625 million, notably below the over $650 million anticipated by analysts. The company attributes this shortfall to supply constraints for certain compounds, which it estimates will reduce revenue by about $65 million.

Pivoting Strategy Through Acquisition

In a strategic shift aimed at reducing reliance on the turbulent U.S. weight-loss market, Hims & Hers has announced a major acquisition. The company plans to purchase digital health provider Eucalyptus for roughly $1.15 billion. This move is designed to significantly accelerate international expansion into markets including the United Kingdom, Germany, and Japan, thereby diversifying its business model.

Wall Street Reacts with Downgrades

The response from financial analysts has been decisively negative. A wave of price target reductions swept across Wall Street. Morgan Stanley slashed its target nearly in half to $21, while Bank of America took an even more pessimistic stance, setting a fair value estimate of just $12.50. Some experts are drawing parallels between the current legal risks and the protracted opioid litigation within the pharmaceutical sector, also warning that international expansion could pressure profit margins.

Trading at €12.28, the stock has lost nearly 57% year-to-date, placing it precisely at its 52-week low. The company's ability to restore market confidence in the coming quarters will likely hinge on the success of its international diversification strategy via the Eucalyptus deal.